The role of molybdenum in nitrate reduction in higher plants.

D. Spencer,J. G. Wood

DOI: https://doi.org/10.1071/BI9540425

1954-11-01

Australian Journal of Biological Sciences

Abstract:Experiments are described which were designed to locate the molybdenumrequiring step in the chain of reactions involved in nitrate utilization in higher plants.

What problem does this paper attempt to address?

Typical Hemolytic Uremic Syndrome Secondary to Influenza A in a Pediatric Patient With Complex Comorbidities: A Rare Encounter

Muawia Ahmed,Raghad A Alghorayed,Ehab Hanafy,Mohammed Kamal,Yassir Mb,Wessam Soliman,Mustafa M Altoonisi

DOI: https://doi.org/10.7759/cureus.65746

2024-07-30

Cureus

Abstract:Hemolytic uremic syndrome (HUS) is a severe condition characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). It can be atypical, due to complement dysregulation, or typical, primarily linked to bacterial infections, with viral-induced HUS being extremely rare. We report the case of a six-year-old male who presented with eight days of upper respiratory tract infection symptoms. Initial treatment for tonsillitis was ineffective. He was admitted to the Pediatric Intensive Care Unit (PICU) with severe dehydration, high-grade fever, and AKI, and was initially suspected of having multi-system inflammatory syndrome in children (MIS-C). Further investigation confirmed typical HUS, likely secondary to Influenza A. The child required peritoneal dialysis and other supportive treatments until recovery. This case underscores the need to consider viral-induced HUS in pediatric patients with severe infections and complex medical presentations. An interdisciplinary approach and timely interventions were crucial for his recovery. This rare presentation of HUS associated with Influenza A highlights the importance of clinical awareness and the need for further research to improve care strategies for similar cases.
Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit

Ana Sofia Vilardouro,Joana Cachão,Márcia Rodrigues,Filipa Durão,Patrícia Costa-Reis,Ana Rita Sandes,José Esteves da Silva,Leonor Boto,Rosário Stone

DOI: https://doi.org/10.1590/2175-8239-JBN-2021-0206

Abstract:Introduction: A better understanding of hemolytic-uremic syndrome (HUS) pathophysiology significantly changed its treatment and prognosis. The aim of this study is to characterize the clinical features, severity, management, and outcomes of HUS patients. Materials and methods: Retrospective study of HUS patients admitted to a Pediatric Nephrology Unit between 1996 and 2020. Demographic and clinical data regarding etiology, severity, treatment strategies, and patient outcome were collected. Results: Twenty-nine patients with HUS were admitted to our unit, but four were excluded. Median age at diagnosis was two years (2 months - 17 years). Clinical manifestations included diarrhea, vomiting, oliguria, hypertension, and fever. During the acute phase, 14 patients (56%) required renal replacement therapy. Infectious etiology was identified in seven patients (five Escherichia coli and two Streptococcus pneumoniae). Since 2015, 2/7 patients were diagnosed with complement pathway dysregulation HUS and there were no cases of infectious etiology detected. Six of these patients received eculizumab. The global median follow-up was 6.5 years [3 months-19.8 years]. One patient died, seven had chronic kidney disease, four of whom underwent kidney transplantation, one relapsed, and seven had no sequelae. Conclusion: These results reflect the lack of infectious outbreaks in Portugal and the improvement on etiological identification since genetic testing was introduced. The majority of patients developed sequels and mortality was similar to that of other countries. HUS patients should be managed in centers with intensive care and pediatric nephrology with capacity for diagnosis, etiological investigation, and adequate treatment. Long-term follow-up is essential.
A stalk-specific localization of trehalase activity in Dictyostelium discoideum.

B. L. Jefferson,C. Rutherford

DOI: https://doi.org/10.1016/0014-4827(76)90247-0

IF: 4.145

1976-11-01

Experimental Cell Research

Abstract:
Stability of biological father presence as a proxy for family stability: cross-racial associations with the longitudinal development of emotion regulation in toddlerhood.

E. Bocknek,H. Brophy-Herb,H. Fitzgerald,R. Schiffman,Cheri A. Vogel

DOI: https://doi.org/10.1002/imhj.21454

2014-07-01

Infant Mental Health Journal

Abstract:The current study, utilizing data from the National Early Head Start Research and Evaluation Project (Love et al., 2005) explored the relationship between biological father presence and emotion regulation over toddlerhood among children from low-income families. Conceptualizing biological father presence as a proxy for family role development, results are interpreted from a role development theoretical perspective. The latent growth curve model was compared based on child ethnoracial status (African American, Caucasian, Hispanic) and child gender. Consistent biological father presence was associated with toddlers' regulatory development across toddlerhood, and this relationship was most robust among Caucasian toddlers as compared to African American toddlers. Findings for Hispanic toddlers were not significantly different from those of Caucasian or African American families. Results bolster the literature on father presence and child outcomes. Analyses address consistency in father presence as a proxy for coherent role development and define a link between consistent father presence and children's regulatory development, demonstrating ethnoracial differences which are likely attributed to the social construction of family roles.
An Unusual Case of Clostridium Difficile Colitis and Hemolytic Uremic Syndrome in a Teenager

Kingshuk Dasgupta,Arvin Santos,Kelly McCaul

Abstract:The term hemolytic uremic syndrome (HUS) refers to a heterogenous group of disorders arising from an initial endothelial cell injury with fibrin and platelet thrombi formation in the vasculature, leading to severe organ damage resulting in the well-known triad of microangiopathic hemolytic anemia, thrombocytopenia and kidney disease. The majority of pediatric cases (90 percent) of HUS are caused by Shiga toxin-producing Escherichia coli (STEC-HUS) or Shigella dysenteriae and rarely with Streptococcus pneumoniae (Pneumococcal-HUS). Atypical hemolytic uremic syndrome (aHUS) constitute only 5 percent of all HUS cases and are mediated by dysregulation of complement proteins. Supportive therapy is the cornerstone of management of HUS. Atypical HUS on the other hand is amenable to treatment with eculizumab; the first FDA approved complement blocker. We present a case of HUS caused by Clostridium difficile in a 16-year-old pediatric patient which has rarely been mentioned in the literature and is the first reported case successfully treated with eculizumab with rapid and sustained improvement in hematologic and kidney disease.
The influence of temperature and fibril stability on degradation of cartilage collagen by rheumatoid synovial collagenase.

E. D. Harris,P. A. McCroskery

DOI: https://doi.org/10.1056/NEJM197401032900101

IF: 158.5

1974-01-03

New England Journal of Medicine

Abstract:Abstract Crude synovial collagenase, an enzyme that may affect joint cartilage in rheumatoid arthritis, can destroy whole articular cartilage. To study this phenomenon under more specific conditions, we purified collagenase synthesized by primary cultures of rheumatoid synovium and used it to degrade collagen fibrils purified from human articular cartilage. These highly cross-linked fibrils were resistant to solubilization in acetic acid-pepsin extracts and, in comparison with skin collagen fibrils reconstituted without intermolecular cross-links, were somewhat resistant to the collagenase as well. However, the rate of cartilage collagen lysis was affected by changes in reaction temperature. At temperatures found within rheumatoid knee joints (36°C) collagenolysis was four times greater than at temperatures found in normal knee joints (33°C). Part of the benefit from anti-inflammatory therapy in rheumatoid arthritis may be secondary to decreasing intra-articular temperatures, thereby decreasing the rate a...
A Case of Suspected Streptococcus Pneumoniae Hemolytic Uremic Syndrome (pHUS) with Utilization of Minor Crossmatching for Platelet Blood Products Lead to a Diagnosis of Atypical Hemolytic Uremic Syndrome (aHUS)

Yi Tat Tong,Suhair Al-Salihi,Tatiana Belousova,Yu Bai,Kimberly Klein,Hlaing Tint,Brian Castillo

Abstract:Background: The action of bacterial neuraminidase of Streptococcus pneumoniae (SPN) results in exposure of the normally "hidden" Thomsen-Freidenreich antigen (T-antigen) found on erythrocytes and other tissues. This may lead to SPN-induced hemolytic uremic syndrome (pHUS) with subsequent hemolysis and end organ damage. pHUS can be identified by minor crossmatch incompatibility. We present a case of suspected pHUS that resulted in a compatible minor crossmatch which led to concern and eventually diagnosis of atypical HUS (aHUS). Design: A 6-month-old boy presented with respiratory failure. He was found to have blood cultures positive for SPN. Shiga toxin was negative and he had normal levels of ADAMTS 13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). The clinical team was concerned for pHUS and requested washed platelet product prior to a surgical procedure. Alternatively, a minor crossmatching was performed to determine the presence of T activation. An aHUS genetic panel was performed to sequence and analyze 12 genes encoding complement factors. Results: Minor crossmatch was performed using the patient's erythrocytes and plasma of ABO-identical platelets to be transfused. No agglutination was seen at immediate spin, 37°C, or anti-human globulin phase with valid controls. Genetics testing for complement mutations was consistent with aHUS. Conclusions: We present a case that is clinically consistent with pHUS. Confirmation of this entity is done with lectins or anti-sera that are not readily available. An alternative means of identifying pHUS is by demonstrating minor crossmatch incompatibility. By doing so, we excluded the possibility of pHUS and helped to elucidate a definitive diagnosis of aHUS. Our goal is to share our experience of a practical approach in a time-sensitive situation that other clinical pathologists could utilize in suspected cases of T activation with a clinical picture of thrombotic microangiopathy.
A Rare Case of Atypical Hemolytic Uremic Syndrome (HUS) in an Adult Male: A Catastrophic Presentation

Sindhu C Pokhriyal,Samuel Sule-Saa,Jemima A Alemonai,Muthanna Mohammed Hasan Al-Ghuraibawi,Luckencia Pierre,Sunil Parkash,Kalpana Panigrahi

DOI: https://doi.org/10.7759/cureus.62590

2024-06-18

Cureus

Abstract:Atypical hemolytic uremic syndrome (HUS) is extremely rare in adults. HUS is characterized by hallmark features of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury. Atypical HUS (aHUS) is caused by uncontrolled complement activation. The complement activation can be triggered by infections such as Streptococcus pneumoniae or influenza, pregnancy, malignancy, cytotoxic drugs, organ transplants, or autoimmune diseases. Genetic mutations and autoantibodies have been found to play a crucial role in the pathogenesis of dysregulated complement activity. The majority of cases of atypical HUS due to invasive S. pneumoniae infection are more commonly seen in children. We present a case of S. pneumoniae HUS (Sp-HUS) presenting with multiorgan failure, disseminated intravascular coagulation (DIC), and limb ischemia in an adult. This case highlights the importance of considering S. pneumoniae HUS (Sp-HUS) in the differential diagnosis of thrombotic microangiopathies (TMA) in adults.
Management of pediatric hemolytic uremic syndrome

Bora Gülhan,Fatih Özaltın,Kibriya Fidan,Zeynep Birsin Özçakar,Oğuz Söylemezoğlu

DOI: https://doi.org/10.24953/turkjped.2023.596

2024-02-28

The Turkish Journal of Pediatrics

Abstract:Classical clinical triad of hemolytic uremic syndrome (HUS) is microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury associated with endothelial cell injury. Several situations, including infections, medications, malignancies, and transplantation can trigger endothelial damage. On the HUS spectrum, atypical hemolytic uremic syndrome (aHUS) deserves special attention in pediatric patients, as it can cause end-stage kidney disease and mortality. A dysfunction in the alternative complement pathway, either acquired or genetic, has been shown to be the main underlying cause. In the last decades, breathtaking advances have been made in understanding the pathophysiology of this rare disease, which has led to more efficient treatment. Recent studies have implicated genes in pathways beyond the alternative complement system, such as DGKE, TSEN2, and INF2 highlighting the importance of personalized management. Eculizumab has brought about dramatic improvements in the treatment of aHUS. Beyond eculizumab, there are many alternative therapeutics in the pipeline that target the complement system. Because of the rarity of aHUS, data from multiple patient registries are very important. The present report aimed to summarize the most important aspects of diagnosing and treating aHUS based on the Turkish national registry and the literature so as to improve clinical practice.

pediatrics
Pediatric Pneumococcal Hemolytic Uremic Syndrome Treated with Sequence Tandem Therapeutic Plasma Exchange and Continuous Venovenous Hemodiafiltration: A Case Report

Josko Markic,Branka Polic,Tanja Kovacevic,Marijana Rogulj,Tatjana Ardalic,Tatjana Catipovic Ardalic

DOI: https://doi.org/10.1055/s-0040-1721450

2020-01-01

Journal of Child Science

Abstract:Abstract Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Approximately 5% of HUS cases are associated with Streptococcus pneumoniae infections (pHUS). Treatment includes supportive care with appropriate antimicrobial therapy, fluid and blood product resuscitation, and renal replacement therapy. We presented a case of a 22-month-old previously healthy girl, who was hospitalized at University Hospital of Split. Left-sided pneumonia and sepsis caused by S. pneumoniae were confirmed. The course of illness was complicated with development of pHUS. Since the pathogenesis of pHUS is only partially understood, the treatment remains controversial. Our patient was successfully treated with daily sequence tandem continuous venovenous hemodiafiltration and therapeutic plasma exchange with albumins, along with other supportive measures. Therefore, in our opinion, plasmapheresis should be considered as a part of standard treatment of children with pHUS. Additionally, the incidence of pHUS appears to be increasing. S. pneumoniae is a particularly important among pediatric pathogens and it can cause wide spectrum of illnesses. Therefore, due to the significant burden of invasive pneumococcal disease, pneumococcal vaccination should be encouraged.
Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)

Johanna Scheiring,Sharon P. Andreoli,Lothar Bernd Zimmerhackl

DOI: https://doi.org/10.1007/s00467-008-0935-6

2008-10-01

Pediatric Nephrology

Abstract:Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in childhood and the reason for chronic renal replacement therapy. It leads to significant morbidity and mortality during the acute phase. In addition to acute morbidity and mortality, long-term renal and extrarenal complications can occur in a substantial number of children years after the acute episode of HUS. The most common infectious agents causing HUS are enterohemorrhagic Escherichia coli (EHEC)-producing Shiga toxin (and belonging to the serotype O157:H7) and several non-O157:H7 serotypes. D+ HUS is an acute disease characterized by prodromal diarrhea followed by acute renal failure. The classic clinical features of HUS include the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS mortality is reported to be between 3% and 5%, and death due to HUS is nearly always associated with severe extrarenal disease, including severe central nervous system (CNS) involvement. Approximately two thirds of children with HUS require dialysis therapy, and about one third have milder renal involvement without the need for dialysis therapy. General management of acute renal failure includes appropriate fluid and electrolyte management, antihypertensive therapy if necessary, and initiation of renal replacement therapy when appropriate. The prognosis of HUS depends on several contributing factors. In general “classic” HUS, induced by EHEC, has an overall better outcome. Totally different is the prognosis in patients with atypical and particularly recurrent HUS. However, patients with severe disease should be screened for genetic disorders of the complement system or other underlying diseases.

pediatrics,urology & nephrology
Hemolytic uremic syndrome with Mycoplasma pneumoniae infection and membrane cofactor protein mutation – case report

Monika Miklaszewska,Katarzyna Zachwieja,Dorota Drożdż,Éva Pállinger,Beáta Takács,Ágnes Szilágyi,Dorottya Csuka,Zoltán Prohászka

Abstract:Thrombotic microangiopathies (TMA) are rare life-threatening diseases of various etiologies, making the identification of the specific forms and appropriate treatment difficult. The aim of this work is to present the history of a patient with atypical hemolytic uremic syndrome (aHUS) that developed in the context of Mycoplasma pneumoniae infection. Case presentation: A 5 - year old, Caucasian, previously healthy girl presented with symptoms of HUS, without preceding diarrhoea and with ongoing upper respiratory tract infection. ADAMTS13 deficiency and presence of Shiga-like toxin producing E. coli (STEC) was excluded, and the diagnosis of aHUS verified. She required peritoneal dialysis for 4 days and fresh frozen plasma (FFP) treatment was started with good clinical response. Serological investigation for Mycoplasma pneumoniae was positive (IgM) leading to the initiation of clarithromycin therapy. The complement profile (classical pathway activity, C3 and C4 serum levels were slightly decreased, no signs of alternative pathway dysregulation) was indicative for classical pathway activation and consumption. The genetic screening revealed a novel non-synonymous variation in the CD46 (MCP) gene in heterozygous form that causes a proline to leucine change at codon 155 of the MCP (P155L). The CD46 P155L variation was associated in the samples of the patient and family members with decreased MCP protein expression on the surface of granulocytes. In addition to the P155L mutation, multiple frequent aHUS risk variations were also identified. Conclusion: The diagnosis of aHUS is challenging and is based mainly on the exclusion of ADAMTS13 deficient thrombotic thrombocytopenic purpura (TTP) and typical HUS caused by STEC. Our patient had single-episodic HUS in the context of upper-airway infection, and finally a functionally relevant CD46 (MCP) mutation was identified. The complexity of aHUS, and the importance of the requirement for full differential diagnostic workup of all HUS cases is further highlighted by the current case history.
Atypical hemolytic uremic syndrome triggered by varicella infection

Pauline Condom,Jean-Michel Mansuy,Stéphane Decramer,Jacques Izopet,Catherine Mengelle

DOI: https://doi.org/10.1016/j.idcr.2017.04.004

2017-06-24

IDCases

Abstract:Varicella Zoster Virus (VZV) is a well-known virus that belongs to the Herpesviridae family which induces a self-limited disease except in specific cases in particular among stem cell transplant patients. This virus is not known however to trigger atypical Hemolytic Uremic Syndrome (aHUS). Here we report the case of a six-year-old boy who was hospitalized with fever and abdominal pains associated to pruritic and vesicular rash, thrombocytopenia and acute renal failure. He was diagnosed with aHUS precipitated by varicella virus. He was treated by an association of antimicrobials against potential superinfections, plasmapheresis and eculizumab for curative aHUS treatment. This was effective but after 6 months the kidney function remained poor. The current case describes an aHUS associated to varicella infection as demonstrated by the simultaneous occurrence of the viral infection and aHUS manifestations. Apart from typical Hemolytic Uremic Syndrome which is triggered by bacteria mostly Shiga toxin producing Echerichia coli and Streptococcus pneumoniae or Shigella, aHUS may be linked to viral infections such as HIV, EBV and enteroviruses, but very rarely by varicella. This case highlights a possible even rare complication of varicella infection a very common childhood disease. This complication could be avoided by to anti-VZV vaccination.
Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases

Maëlle de Ville de Goyet,Thierry Detaille,Nathalie Godefroid

DOI: https://doi.org/10.1097/MPH.0000000000001449

Abstract:Typical hemolytic uremic syndrome (HUS) in children is caused mostly by Escherichia coli 0157:H7 in our country. Atypical HUS (aHUS) causes include Streptococcus pneumoniae, methyl malonic aciduria, deficiency of ADAMST 13, and genetic or acquired disorder of the complement. Treatment of HUS relies on supportive measures while treatment of aHUS includes plasmapheresis and specific treatments. Recently, eculizumab has been proposed for the treatment of aHUS and many clinicians now believe that eculizumab should be the first-line standard of care. The purpose of this article is to illustrate the difficulties in the diagnostic process of HUS and therefore the subsequent problem to promptly choose the appropriate treatment. To date, workup of HUS continues to take many days leaving the clinicians with a choice between several therapeutic options. With the emergence of eculizumab, it becomes crucial to find faster diagnostic tools and to adapt HUS treatment protocols. We reported here clinical cases where eculizumab use was probably not appropriate once the correct diagnosis of typical HUS was made and cases where it would have been useful because of the late diagnosis of aHUS.
Changes of insulinemia, glycemia and feeding behavior induced by VMH-procainization in the rat

H. Berthoud,B. Jeanrenaud

DOI: https://doi.org/10.1016/0006-8993(79)90816-3

IF: 3.61

1979-09-28

Brain Research

Abstract:
Invasive Streptococcus Pneumoniae Septicemia Complicated with Hemolytic Uremic Syndrome and Meningitis

Vijayakumary Thadchanamoorthy,Kavinda Dayasiri

DOI: https://doi.org/10.7759/cureus.10644

2020-09-25

Cureus

Abstract:Streptococcus pneumoniae-associated hemolytic uremic syndrome (SpHUS) is an uncommon cause of hemolytic uremic syndrome (HUS). The diagnosis and treatment of Streptococcus pneumoniae-associated HUS is often difficult and associated with high long-term morbidity and mortality. The authors report a five-year-old child who developed HUS following an invasive Streptococcus (S.) pneumoniae infection. The child initially presented with fever, cough, and difficulty in breathing for three days duration and was clinically and radiologically diagnosed as having right middle lobe pneumonia. Blood culture grew Streptococcus pneumoniae. The cerebrospinal fluid analysis also showed Streptococcus pneumoniae. He was initially treated with intravenous cefotaxime. As the child had a poor response to cefotaxime with ongoing fever, antibiotics were changed to ceftriaxone and vancomycin. Although fever started to subside subsequently, the child deteriorated with reduced urine output and developed generalized body swelling. The hematological and biochemical evaluation confirmed hemolytic uremic syndrome. He needed continuous renal replacement therapy for five days and antibiotics were given for 14 days. He had no long-term sequelae on follow-up.
The Association between Childhood Asthma and Community Violence, Los Angeles County, 2000

J. Jeffrey,I. Sternfeld,I. Tager

DOI: https://doi.org/10.1177/003335490612100612

2006-11-01

Abstract:Objective. This study's objective is to determine if there is an association between rates of violence and rates of childhood asthma in Los Angeles County communities. Methods. Rates of hospitalization for assault and for asthma were calculated for each ZIP Code and city in Los Angeles County. Linear regression was used to determine the effect of assault rates on asthma rates while controlling for potential confounders such as poverty and racial/ethnic distribution. At the city level, crime rates were included in the model as additional measures of community violence. Results. Hospitalization rates for childhood asthma and assaults were significantly correlated at both the city (r=0.80) and the ZIP Code (r=0.54) levels. The association remained significant when controlling for poverty and racial/ethnic distribution with linear regression (p<0.0001). At the city level, the variables measuring the crime rate were not significant predictors of asthma hospitalizations. Conclusions. Community violence as measured by the rate of assault hospitalizations is associated with childhood asthma in Los Angeles County. Health care providers should consider their asthmatic patients' social environments when devising treatment plans.
Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome

Johannes Holle,Sandra Habbig,Alexander Gratopp,Anna Mauritsch,Dominik Müller,Julia Thumfart

DOI: https://doi.org/10.1007/s00467-021-04952-w

Abstract:Background: Hemolytic uremic syndrome caused by invasive pneumococcal disease (P-HUS) is rare in children and adolescents, but accompanied by high mortality in the acute phase and complicated by long-term renal sequelae. Abnormalities in the alternative complement pathway may additionally be contributing to the course of the disease but also to putative treatment options. Methods: Retrospective study to assess clinical course and laboratory data of the acute phase and outcome of children with P-HUS. Results: We report on seven children (median age 12 months, range 3-28 months) diagnosed with P-HUS. Primary organ manifestation was meningitis in four and pneumonia in three patients. All patients required dialysis which could be discontinued in five of them after a median of 25 days. In two patients, broad functional and genetic complement analysis was performed and revealed alternative pathway activation and risk haplotypes in both. Three patients were treated with the complement C5 inhibitor eculizumab. During a median follow-up time of 11.3 years, one patient died due to infectious complications after transplantation. Two patients showed no signs of renal sequelae. Conclusions: Although pathophysiology in P-HUS remains as yet incompletely understood, disordered complement regulation seems to provide a clue to additional insights for pathology, diagnosis, and even targeted treatment.
99mTc-DMSA scanning and segmental renal vein renin estimations in children with renal scarring.

M. Dillon,I. Gordon,V. Shah

Contributions to Nephrology

Abstract:
Minor Cross-Matching in the Diagnosis of Pneumococcal Hemolytic Uremic Syndrome in an 18-Month-Old Boy

Suman Sudha Routray,Sukanta Tripathy,Palash Das,Gopal Krushna Ray

DOI: https://doi.org/10.1093/labmed/lmac092

2023-03-07

Abstract:In developing nations, limitations in diagnostic facilities act as a barrier for differentiation of hemolytic uremic syndrome (HUS) based on the etiology. A sick-looking 18-month-old boy presented to our hospital in Bhubaneswar, India, with clinical signs and symptoms of left lobar pneumonia, abnormal hematological and renal parameters, no growth in blood culture, a negative direct antiglobulin test (DAT) result, and low complement levels. A rapid deterioration in his clinical condition necessitated intensive care support, blood transfusion, and renal replacement therapy (peritoneal dialysis and hemodialysis). Because his health care team suspected atypical HUS, therapeutic plasma exchange (TPE) was initiated as soon as possible. In the absence of a lectin panel, minor cross-matching confirmed T-antigen exposure. With a diagnosis of HUS induced by Streptococcus pneumoniae (sp-HUS), TPE was stopped immediately, and washed blood components were administered. Despite the aforementioned measures, the boy died of HUS on day 20 after presentation. This case emphasized the role of minor cross-matching in the detecting of polyagglutination in resolving the diagnostic dilemma of sp-HUS.

The role of molybdenum in nitrate reduction in higher plants.

Typical Hemolytic Uremic Syndrome Secondary to Influenza A in a Pediatric Patient With Complex Comorbidities: A Rare Encounter

Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit

A stalk-specific localization of trehalase activity in Dictyostelium discoideum.

Stability of biological father presence as a proxy for family stability: cross-racial associations with the longitudinal development of emotion regulation in toddlerhood.

An Unusual Case of Clostridium Difficile Colitis and Hemolytic Uremic Syndrome in a Teenager

The influence of temperature and fibril stability on degradation of cartilage collagen by rheumatoid synovial collagenase.

A Case of Suspected Streptococcus Pneumoniae Hemolytic Uremic Syndrome (pHUS) with Utilization of Minor Crossmatching for Platelet Blood Products Lead to a Diagnosis of Atypical Hemolytic Uremic Syndrome (aHUS)

A Rare Case of Atypical Hemolytic Uremic Syndrome (HUS) in an Adult Male: A Catastrophic Presentation

Management of pediatric hemolytic uremic syndrome

Pediatric Pneumococcal Hemolytic Uremic Syndrome Treated with Sequence Tandem Therapeutic Plasma Exchange and Continuous Venovenous Hemodiafiltration: A Case Report

Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)

Hemolytic uremic syndrome with Mycoplasma pneumoniae infection and membrane cofactor protein mutation – case report

Atypical hemolytic uremic syndrome triggered by varicella infection

Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases

Changes of insulinemia, glycemia and feeding behavior induced by VMH-procainization in the rat

Invasive Streptococcus Pneumoniae Septicemia Complicated with Hemolytic Uremic Syndrome and Meningitis

The Association between Childhood Asthma and Community Violence, Los Angeles County, 2000

Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome

99mTc-DMSA scanning and segmental renal vein renin estimations in children with renal scarring.

Minor Cross-Matching in the Diagnosis of Pneumococcal Hemolytic Uremic Syndrome in an 18-Month-Old Boy